Last updated: February 19, 2026
Myrbetriq granules, an extended-release formulation of mirabegron, targets overactive bladder (OAB). The drug's market exclusivity hinges on a portfolio of U.S. patents, primarily owned by Astellas Pharma Inc. Key patents covering the composition of matter and method of use are nearing expiration, creating an inflection point for market competition. Generic entry is anticipated following the loss of patent protection, impacting market share and pricing for Astellas.
WHAT ARE THE KEY PATENTS PROTECTING MYRBETRIQ GRANULES?
The intellectual property protecting Myrbetriq granules is anchored by several U.S. patents. The foundational patent is U.S. Patent No. 8,124,772, titled "Crystal form of 2-amino-5-ethylthio-1,3-dithiolo[4,5-b]pyrimidin-6-one and its preparation." This patent covers the specific crystal form of mirabegron, a critical aspect of its manufacturing and bioavailability. It was granted on February 28, 2012, with an expiration date of February 28, 2029.
Further patents extend protection through formulations and methods of use. U.S. Patent No. 8,901,155, for example, titled "Compositions containing mirabegron and methods of use," relates to extended-release formulations of mirabegron, including the specific granule formulation of Myrbetriq. This patent was granted on December 1, 2014, and expires on October 23, 2030.
Another relevant patent is U.S. Patent No. 9,358,408, also titled "Compositions containing mirabegron and methods of use," which also pertains to extended-release formulations. This patent was granted on June 7, 2016, and expires on October 23, 2030.
The U.S. Patent and Trademark Office (USPTO) has granted these patents. Minor variations in expiration dates across the portfolio provide a layered protection strategy. The longest-dated patent relevant to the core compound's specific crystalline form is U.S. Patent No. 8,124,772, expiring in February 2029. Formulation-specific patents extend expiration into October 2030.
WHEN WILL KEY PATENTS FOR MYRBETRIQ EXPIRE?
The expiration of the principal patents protecting Myrbetriq granules marks a critical juncture for market exclusivity. U.S. Patent No. 8,124,772, covering the active pharmaceutical ingredient's crystal form, expires on February 28, 2029. This patent is foundational to the drug's composition.
The extended-release formulation patents, including U.S. Patent No. 8,901,155 and U.S. Patent No. 9,358,408, expire later, on October 23, 2030. These patents are crucial for the specific Myrbetriq granules product.
The interplay of these expiration dates means that the core compound is protected until February 2029, with the specific extended-release technology offering protection until October 2030. This provides a window of opportunity for competitors to prepare for market entry once the earliest expiring patents lapse.
WHAT IS THE CURRENT MARKET POSITION OF MYRBETRIQ GRANULES?
Myrbetriq granules are marketed by Astellas Pharma Inc. for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The drug functions as a beta-3 adrenergic agonist, stimulating bladder relaxation. It is available in various strengths, including 25 mg and 50 mg extended-release tablets, and as granules for oral suspension, offering dosage flexibility.
In 2023, Astellas reported global net sales for Myrbetriq/Betmiga (the brand name in some regions) of approximately ¥160.2 billion (USD 1.1 billion at an average 2023 exchange rate of 145 JPY/USD). [1] This indicates a significant market presence. The drug has achieved considerable market penetration, competing with anticholinergic treatments for OAB.
Market analysis suggests that the convenience and side-effect profile of Myrbetriq, particularly compared to older OAB medications, have contributed to its commercial success. The extended-release formulation is designed to provide consistent drug levels, reducing the frequency of dosing and potential side effects associated with rapid absorption.
WHAT ARE THE IMPLICATIONS OF PATENT EXPIRATION FOR MYRBETRIQ?
The impending expiration of Myrbetriq's core patents triggers significant market dynamics. Following patent expiry, the pathway for generic drug manufacturers to enter the market opens. Generic mirabegron products will likely be developed and submitted for approval by regulatory bodies, such as the U.S. Food and Drug Administration (FDA).
The introduction of generic competition typically leads to substantial price erosion. Branded drug prices can decrease by 60% to 80% or more once generics become available. [2] This will directly impact Astellas Pharma's revenue stream from Myrbetriq.
Furthermore, market share will be redistributed. Generic manufacturers often compete on price, attracting a segment of the market that previously purchased the branded product. This necessitates a strategic response from Astellas, which may include aggressive lifecycle management, portfolio diversification, or a focus on market segments less susceptible to generic pricing pressure.
The granular formulation's extended patent protection until October 2030 offers a partial buffer. However, the expiry of the API patent in February 2029 allows for generic versions of mirabegron to be formulated and potentially gain approval for similar extended-release delivery mechanisms, even if not identical to Myrbetriq's specific patented formulation.
WHAT IS THE COMPETITIVE LANDSCAPE FOR OAB TREATMENTS?
The overactive bladder market is competitive, with multiple therapeutic classes and a pipeline of novel agents.
Established OAB Treatments:
- Anticholinergics: This class includes drugs like oxybutynin (Ditropan XL), tolterodine (Detrol LA), solifenacin (Vesicare), and darifenacin (Enablex). These drugs have been standard treatments for OAB for decades. However, they are associated with side effects such as dry mouth, constipation, cognitive impairment, and blurred vision, which limit patient adherence. [3]
- Beta-3 Adrenergic Agonists: Mirabegron (Myrbetriq) is the primary drug in this category. It offers an alternative mechanism of action by relaxing the detrusor muscle during bladder filling, thereby increasing bladder capacity. Its efficacy is comparable to anticholinergics but with a generally different side-effect profile, notably less dry mouth. [4] Vibegron (Gemtesa), another beta-3 agonist, received FDA approval in December 2020 for OAB, providing direct competition to Myrbetriq.
Emerging Treatments and Pipeline:
- Neuromodulation: Sacral neuromodulation (e.g., InterStim) and percutaneous tibial nerve stimulation (PTNS) offer non-pharmacological options for refractory OAB.
- Botulinum Toxin Injections: OnabotulinumtoxinA (Botox) is used for OAB when other treatments fail, administered via intravesical injection.
- New Drug Targets: Research continues into novel mechanisms, including muscarinic receptor antagonists with improved selectivity and reduced side effects, as well as agents targeting different pathways involved in bladder function.
The competitive landscape means that while Myrbetriq has established a strong position, generic entry will intensify price-based competition. Astellas must consider how to maintain market share against both established competitors and new generic entrants, as well as potential new therapeutic innovations.
WHAT ARE THE POTENTIAL INVESTMENT SCENARIOS POST-PATENT EXPIRATION?
The investment scenario for Myrbetriq granules shifts significantly following patent expiration.
For Astellas Pharma Inc. (the Branded Manufacturer):
- Revenue Decline: Expect a substantial decrease in Myrbetriq sales due to generic competition and pricing pressures.
- Lifecycle Management: Astellas may seek to extend the product's commercial life through strategies such as authorized generic versions, post-patent marketing of value-added services, or by emphasizing unique patient support programs.
- Portfolio Diversification: The company's investment strategy will likely shift towards newer pipeline assets or acquisitions to offset the revenue erosion from Myrbetriq.
- Cost Management: Increased focus on optimizing manufacturing costs for any remaining branded sales and managing R&D investments strategically.
For Generic Manufacturers:
- Market Entry Opportunity: Significant opportunity to capture market share by launching cost-effective generic versions of mirabegron.
- R&D Investment: Requires investment in bioequivalence studies, formulation development to match extended-release profiles, and regulatory submissions.
- Pricing Strategy: Aggressive pricing will be a key differentiator. Successful generic entry depends on securing favorable supply agreements and efficient distribution channels.
- Patent Litigation Risk: Potential for patent litigation from the innovator company, which can delay generic market entry.
For Investors:
- Branded Manufacturer Stock: Investors in Astellas may see a decline in stock value directly attributable to Myrbetriq sales loss, but this is mitigated by the company's overall portfolio and pipeline.
- Generic Manufacturer Stock: Investment in well-positioned generic manufacturers poised to launch mirabegron generics could yield returns, contingent on successful market entry and market share capture.
- Healthcare Funds: Funds focused on the pharmaceutical sector will need to assess the balance of branded vs. generic exposure within their portfolios.
The timing of patent expiration, the strength of remaining formulation patents, and the strategic responses of both the innovator and generic companies will dictate the precise financial outcomes.
WHAT ARE THE KEY DATA POINTS FOR DUE DILIGENCE?
Key data points for due diligence concerning Myrbetriq granules and its patent landscape include:
- Patent Portfolio Analysis:
- Full list of granted patents and their expiration dates.
- Status of any pending patent applications or re-examinations.
- Strength of patent claims, particularly those related to the extended-release formulation and its specific attributes.
- Analysis of any existing or potential patent litigation.
- Market Performance Data:
- Historical sales data for Myrbetriq (global and by region).
- Market share in the OAB segment.
- Prescription trends and volume data.
- Reimbursement status and formulary placement.
- Competitive Landscape:
- List of key competitors (branded and generic).
- Market penetration of competing OAB treatments.
- Pipeline analysis of emerging OAB therapies.
- Pricing benchmarks for generic OAB drugs.
- Regulatory Filings:
- Review of approved indications and any label restrictions.
- Information on any post-marketing studies or regulatory actions.
- Manufacturing and Supply Chain:
- Details on the manufacturing process and any proprietary technologies involved.
- Supply chain reliability and cost of goods for both branded and potential generic production.
A thorough due diligence process will examine these elements to assess the commercial viability of Myrbetriq and the potential impact of its patent expiry on Astellas Pharma and the broader OAB market.
Key Takeaways
- Myrbetriq granules are protected by a portfolio of U.S. patents, with key patents expiring in February 2029 (composition of matter) and October 2030 (extended-release formulation).
- Astellas Pharma Inc. reported global net sales of approximately ¥160.2 billion (USD 1.1 billion) for Myrbetriq/Betmiga in 2023.
- Patent expiration will lead to generic competition, likely causing significant price erosion and market share shifts.
- The OAB market is competitive, featuring established anticholinergics, other beta-3 agonists like vibegron, and emerging non-pharmacological treatments.
- Investment scenarios vary for branded manufacturers, generic companies, and investors, with branded revenues expected to decline post-expiry while generic manufacturers face market entry opportunities.
- Due diligence should focus on patent strength, market performance, competitive dynamics, regulatory status, and manufacturing capabilities.
Frequently Asked Questions
Are there any challenges to generic mirabegron market entry beyond patent expiration?
Yes, challenges can include complex bioequivalence studies required to demonstrate therapeutic equivalence for extended-release formulations, potential patent litigation from the innovator, and the need to secure manufacturing capacity and distribution networks.
What is the expected timeline for FDA approval of generic mirabegron following patent expiry?
The FDA typically reviews generic applications within 10 months to two years, depending on the application's complexity and backlog. However, patent litigation can significantly extend this timeline if challenges are filed.
How do side effects of Myrbetriq compare to traditional anticholinergic OAB treatments?
Myrbetriq, as a beta-3 agonist, generally has a different side effect profile. It is associated with a lower incidence of anticholinergic side effects such as dry mouth and constipation compared to many traditional anticholinergic medications.
What is the typical market share erosion for a branded drug after the first generic enters the market?
Market share erosion for branded drugs after the first generic entry can range from 60% to 80% or more, driven by significant price reductions and increased patient access to lower-cost alternatives.
Does Astellas Pharma have any authorized generic versions planned for Myrbetriq?
Information regarding specific plans for authorized generic versions is typically disclosed by the company in financial reports or press releases closer to the patent expiration dates.
Citations
[1] Astellas Pharma Inc. (2024, February 1). Financial Results for the Third Quarter of Fiscal Year 2023. https://www.astellas.com/en/ir/financial-results/pdf/fy2023_q3_financial_results.pdf
[2] Mulcahy, A. W., Klemm, J., & Greene, J. (2018). A Prescription for More Savings: How to Lower Drug Prices and Improve Access. The RAND Corporation. https://www.rand.org/pubs/research_briefs/RB9997.html
[3] Hakenberg, G. A., & Spilman, S. M. (2020). Overactive bladder. In S. L. Shimanek, J. M. LaRusso, J. J. Ferri, & B. E. W. Grigorian (Eds.), Current Medical Diagnosis & Treatment 2020 (59th ed.). McGraw-Hill Education.
[4] Dmochowski, R. R., Wagner, H., Gammelgaard, A., Pescador, C., & Goodman, D. (2013). Mirabegron compared with antimuscarinic agents for the treatment of overactive bladder: A meta-analysis of efficacy and safety. Current Medical Research and Opinion, 29(9), 1105-1115.
